JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2013, Volume 62, Issue 21, pp. 1966 - 1976
Objectives This study sought to investigate the role of secretory phospholipase A2 (sPLA2 )-IIA in cardiovascular disease. Background Higher circulating levels...
Cardiovascular | Internal Medicine | drug development | epidemiology | genetics | cardiovascular diseases | Mendelian randomization | Studies | Cardiovascular disease | Heart attacks | Drug therapy | Mortality | Cholesterol
Cardiovascular | Internal Medicine | drug development | epidemiology | genetics | cardiovascular diseases | Mendelian randomization | Studies | Cardiovascular disease | Heart attacks | Drug therapy | Mortality | Cholesterol
Journal Article
Surgical Neurology, ISSN 0090-3019, 2009, Volume 72, Issue 5, pp. 461 - 463
Abstract Background The frequency of spontaneous CSF rhinorrhea in macroprolactinoma patients is poorly documented and was previously thought to be a very rare...
Neurology | Surgery | Cabergoline | CSF rhinorrhea | Macroprolactinoma | SURGERY | PROLACTINOMA | BROMOCRIPTINE | CLINICAL NEUROLOGY | INVASIVE MACROPROLACTINOMA | Cavernous Sinus - diagnostic imaging | Pituitary Neoplasms - surgery | Sphenoid Bone - surgery | Sphenoid Sinus - pathology | Humans | Middle Aged | Clinical Protocols | Male | Tomography, X-Ray Computed | Neurosurgical Procedures - standards | Sphenoid Sinus - diagnostic imaging | Nasal Cavity - pathology | Neoplasm Invasiveness - pathology | Sphenoid Bone - pathology | Adult | Cerebrospinal Fluid Rhinorrhea - pathology | Female | Retrospective Studies | Prolactinoma - drug therapy | Sphenoid Sinus - surgery | Prolactinoma - pathology | Prolactinoma - surgery | Cerebrospinal Fluid Rhinorrhea - etiology | Prolactin - secretion | Cavernous Sinus - pathology | Risk Assessment | Pituitary Gland - pathology | Pituitary Gland - surgery | Biomarkers - analysis | Pituitary Gland - diagnostic imaging | Pituitary Neoplasms - pathology | Biomarkers - blood | Sphenoid Bone - diagnostic imaging | Disease Progression | Nasal Cavity - surgery | Neoplasm Invasiveness - physiopathology | Prolactin - blood | Magnetic Resonance Imaging | Pituitary Neoplasms - drug therapy | Craniotomy - methods | Craniotomy - standards | Cerebrospinal Fluid Rhinorrhea - surgery | Prolactin - analysis
Neurology | Surgery | Cabergoline | CSF rhinorrhea | Macroprolactinoma | SURGERY | PROLACTINOMA | BROMOCRIPTINE | CLINICAL NEUROLOGY | INVASIVE MACROPROLACTINOMA | Cavernous Sinus - diagnostic imaging | Pituitary Neoplasms - surgery | Sphenoid Bone - surgery | Sphenoid Sinus - pathology | Humans | Middle Aged | Clinical Protocols | Male | Tomography, X-Ray Computed | Neurosurgical Procedures - standards | Sphenoid Sinus - diagnostic imaging | Nasal Cavity - pathology | Neoplasm Invasiveness - pathology | Sphenoid Bone - pathology | Adult | Cerebrospinal Fluid Rhinorrhea - pathology | Female | Retrospective Studies | Prolactinoma - drug therapy | Sphenoid Sinus - surgery | Prolactinoma - pathology | Prolactinoma - surgery | Cerebrospinal Fluid Rhinorrhea - etiology | Prolactin - secretion | Cavernous Sinus - pathology | Risk Assessment | Pituitary Gland - pathology | Pituitary Gland - surgery | Biomarkers - analysis | Pituitary Gland - diagnostic imaging | Pituitary Neoplasms - pathology | Biomarkers - blood | Sphenoid Bone - diagnostic imaging | Disease Progression | Nasal Cavity - surgery | Neoplasm Invasiveness - physiopathology | Prolactin - blood | Magnetic Resonance Imaging | Pituitary Neoplasms - drug therapy | Craniotomy - methods | Craniotomy - standards | Cerebrospinal Fluid Rhinorrhea - surgery | Prolactin - analysis
Journal Article
The Lancet, ISSN 0140-6736, 11/2017, Volume 390, pp. S40 - S40
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1016/S0140-6736(17)32975-6...
Medicine, Experimental | Medical research | Models | Algorithms | Cardiovascular diseases | Risk factors | Prediction models | Health risks | Fitness
Medicine, Experimental | Medical research | Models | Algorithms | Cardiovascular diseases | Risk factors | Prediction models | Health risks | Fitness
Journal Article
Annals of Emergency Medicine, ISSN 0196-0644, 06/2019, Volume 73, Issue 6, pp. 650 - 661
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10080, pp. 1710 - 1718
Summary Background Stricturing and penetrating complications account for substantial morbidity and health-care costs in paediatric and adult onset Crohn's...
Internal Medicine | MEDICINE, GENERAL & INTERNAL | THERAPY | INFLIXIMAB | RESECTION | ILEAL | Medicine, Experimental | Medical research | Children | Analysis | Diseases | Pediatrics | Therapy | Pathogenesis | Antiinfectives and antibacterials | Gastroenterology | Classification | Gangrene | Extracellular matrix | Mathematical models | Diagnosis | Genotypes | Chronic illnesses | Complications | Health risks | Inflammation | Crohn's disease | Gene expression | Patients | Morbidity | Crohns disease | Inflammatory bowel disease | Tumor necrosis factor | Medical prognosis | Rectum | Predictions | Colitis | Tumors
Internal Medicine | MEDICINE, GENERAL & INTERNAL | THERAPY | INFLIXIMAB | RESECTION | ILEAL | Medicine, Experimental | Medical research | Children | Analysis | Diseases | Pediatrics | Therapy | Pathogenesis | Antiinfectives and antibacterials | Gastroenterology | Classification | Gangrene | Extracellular matrix | Mathematical models | Diagnosis | Genotypes | Chronic illnesses | Complications | Health risks | Inflammation | Crohn's disease | Gene expression | Patients | Morbidity | Crohns disease | Inflammatory bowel disease | Tumor necrosis factor | Medical prognosis | Rectum | Predictions | Colitis | Tumors
Journal Article
Lancet Neurology, The, ISSN 1474-4422, 2014, Volume 13, Issue 11, pp. 1083 - 1091
Summary Background Glutamate excitotoxicity might contribute to the pathophysiology of amyotrophic lateral sclerosis. In animal models, decreased excitatory...
Neurology | SURVIVAL | STROKE | NERVOUS-SYSTEM | RILUZOLE | INFECTIONS | MODELS | GLUTAMATE | ALS | CEREBROSPINAL-FLUID | EXPRESSION | CLINICAL NEUROLOGY | Dyspnea - chemically induced | Double-Blind Method | Dyspnea - diagnosis | Humans | Middle Aged | Amyotrophic Lateral Sclerosis - diagnosis | Male | Treatment Outcome | Amyotrophic Lateral Sclerosis - drug therapy | Ceftriaxone - therapeutic use | Ceftriaxone - adverse effects | Adult | Female | Aged | Clinical trials | Medical colleges | Amyotrophic lateral sclerosis | Nervous system diseases | Glutamate | Analysis | Disease | Laboratories | Hispanic Americans | Family medical history | Quality of life | Studies | Hospitals | Antibiotics | Neurodegeneration | Pharmacy | Drug dosages | Drug stores | Inventory
Neurology | SURVIVAL | STROKE | NERVOUS-SYSTEM | RILUZOLE | INFECTIONS | MODELS | GLUTAMATE | ALS | CEREBROSPINAL-FLUID | EXPRESSION | CLINICAL NEUROLOGY | Dyspnea - chemically induced | Double-Blind Method | Dyspnea - diagnosis | Humans | Middle Aged | Amyotrophic Lateral Sclerosis - diagnosis | Male | Treatment Outcome | Amyotrophic Lateral Sclerosis - drug therapy | Ceftriaxone - therapeutic use | Ceftriaxone - adverse effects | Adult | Female | Aged | Clinical trials | Medical colleges | Amyotrophic lateral sclerosis | Nervous system diseases | Glutamate | Analysis | Disease | Laboratories | Hispanic Americans | Family medical history | Quality of life | Studies | Hospitals | Antibiotics | Neurodegeneration | Pharmacy | Drug dosages | Drug stores | Inventory
Journal Article
American Journal of Cardiology, The, ISSN 0002-9149, 2007, Volume 99, Issue 12, pp. S21 - S33
Most patients with type 2 diabetes mellitus develop cardiovascular disease (CVD), with substantial loss of life expectancy. Nonfatal CVD contributes greatly to...
Cardiovascular | CARDIAC & CARDIOVASCULAR SYSTEMS | RATIONALE | DISEASE | ADULTS | PREVENTION | MELLITUS | HEALTH | INTERVENTION | STRATEGIES | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Humans | Coronary Artery Disease - prevention & control | Fenofibrate - administration & dosage | Diabetic Angiopathies - blood | Coronary Artery Disease - blood | Fenofibrate - therapeutic use | Patient Selection | Randomized Controlled Trials as Topic | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Glycated Hemoglobin A | Hypolipidemic Agents - administration & dosage | Diabetes Mellitus, Type 2 | Hypolipidemic Agents - therapeutic use | Diabetic Angiopathies - prevention & control | Research Design | Obesity | Diabetics | Anticholesteremic agents | Clinical trials | Diabetes | Cardiovascular diseases | Blood lipoproteins | Health aspects | Risk factors | Methods | Diabetes therapy
Cardiovascular | CARDIAC & CARDIOVASCULAR SYSTEMS | RATIONALE | DISEASE | ADULTS | PREVENTION | MELLITUS | HEALTH | INTERVENTION | STRATEGIES | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Humans | Coronary Artery Disease - prevention & control | Fenofibrate - administration & dosage | Diabetic Angiopathies - blood | Coronary Artery Disease - blood | Fenofibrate - therapeutic use | Patient Selection | Randomized Controlled Trials as Topic | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Glycated Hemoglobin A | Hypolipidemic Agents - administration & dosage | Diabetes Mellitus, Type 2 | Hypolipidemic Agents - therapeutic use | Diabetic Angiopathies - prevention & control | Research Design | Obesity | Diabetics | Anticholesteremic agents | Clinical trials | Diabetes | Cardiovascular diseases | Blood lipoproteins | Health aspects | Risk factors | Methods | Diabetes therapy
Journal Article
Journal of the American College of Surgeons, ISSN 1072-7515, 2017, Volume 225, Issue 1, pp. 42 - 51
Abstract Background Altered coagulation function after trauma may contribute to venous thromboembolism (VTE) development. Severe trauma impairs coagulation...
Surgery | CLOT FORMATION | HYPERCOAGULABILITY | SURGERY | THROMBOSIS | PULMONARY-EMBOLISM | PLATELET-FUNCTION | RISK | COAGULOPATHY | THROMBOPROPHYLAXIS | FIBRINOGEN | PATHOPHYSIOLOGY | Thrombelastography | Humans | Middle Aged | Wounds and Injuries - complications | Trauma Centers | Anticoagulants - therapeutic use | Male | Recovery of Function | Venous Thromboembolism - drug therapy | Injury Severity Score | Venous Thromboembolism - etiology | Blood Coagulation Tests | Adult | Female | Venous Thromboembolism - diagnostic imaging | Blood Coagulation Disorders - complications | Thromboembolism | Thrombin | Analysis | trauma | coagulopathy | platelet function | venous thromboembolism
Surgery | CLOT FORMATION | HYPERCOAGULABILITY | SURGERY | THROMBOSIS | PULMONARY-EMBOLISM | PLATELET-FUNCTION | RISK | COAGULOPATHY | THROMBOPROPHYLAXIS | FIBRINOGEN | PATHOPHYSIOLOGY | Thrombelastography | Humans | Middle Aged | Wounds and Injuries - complications | Trauma Centers | Anticoagulants - therapeutic use | Male | Recovery of Function | Venous Thromboembolism - drug therapy | Injury Severity Score | Venous Thromboembolism - etiology | Blood Coagulation Tests | Adult | Female | Venous Thromboembolism - diagnostic imaging | Blood Coagulation Disorders - complications | Thromboembolism | Thrombin | Analysis | trauma | coagulopathy | platelet function | venous thromboembolism
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2016, Volume 16, Issue 1, pp. 43 - 52
Summary Background Antiretroviral regimens containing tenofovir disoproxil fumarate have been associated with renal toxicity and reduced bone mineral density....
Infectious Disease | LONG-TERM | GLOMERULAR-FILTRATION-RATE | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | BONE-MINERAL DENSITY | DOUBLE-BLIND | INITIAL TREATMENT | SINGLE-TABLET REGIMEN | CHRONIC KIDNEY-DISEASE | ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR DF | CKD-EPI | HIV-1 | Adenine - analogs & derivatives | Tenofovir - therapeutic use | Humans | Middle Aged | Male | CD4 Lymphocyte Count | Viral Load | Adenine - administration & dosage | Adenine - therapeutic use | RNA, Viral | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Drug Combinations | Tenofovir | Highly active antiretroviral therapy | Bones | Cross infection | Nosocomial infections | HIV (Viruses) | Density | HIV infection | Osteoporosis | Laboratories | Human immunodeficiency virus--HIV | Collaboration | Infections | Bone density | Kidney diseases | Drug dosages | Epidemiology
Infectious Disease | LONG-TERM | GLOMERULAR-FILTRATION-RATE | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | BONE-MINERAL DENSITY | DOUBLE-BLIND | INITIAL TREATMENT | SINGLE-TABLET REGIMEN | CHRONIC KIDNEY-DISEASE | ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR DF | CKD-EPI | HIV-1 | Adenine - analogs & derivatives | Tenofovir - therapeutic use | Humans | Middle Aged | Male | CD4 Lymphocyte Count | Viral Load | Adenine - administration & dosage | Adenine - therapeutic use | RNA, Viral | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Drug Combinations | Tenofovir | Highly active antiretroviral therapy | Bones | Cross infection | Nosocomial infections | HIV (Viruses) | Density | HIV infection | Osteoporosis | Laboratories | Human immunodeficiency virus--HIV | Collaboration | Infections | Bone density | Kidney diseases | Drug dosages | Epidemiology
Journal Article
JACC: Heart Failure, ISSN 2213-1779, 2017, Volume 5, Issue 5, pp. 317 - 326
Abstract Objectives The objective of this clinical trial was to evaluate the long-term effect of endothelin receptor antagonism with bosentan on the morbidity...
Cardiovascular | clinical trial | endothelin | heart failure | bosentan | placebo
Cardiovascular | clinical trial | endothelin | heart failure | bosentan | placebo
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 11/2013, Volume 62, Issue 21, pp. 1966 - 1976
Objectives This study sought to investigate the role of secretory phospholipase A(2) (sPLA(2))-IIA in cardiovascular disease. Background Higher circulating...
EVENTS | drug development | RISK | ACUTE CORONARY SYNDROMES | cardiovascular diseases | Mendelian randomization | TRIAL | epidemiology | genetics | EPIC-NORFOLK | SERUM-LEVELS | INHIBITOR | HEALTHY-MEN | ARTERY-DISEASE | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | ACUTE CORONARY SYNDROME | ENZYMES | ASSOCIATION | TEKNIKVETENSKAP | Engineering and Technology | Teknik och teknologier | TECHNOLOGY
EVENTS | drug development | RISK | ACUTE CORONARY SYNDROMES | cardiovascular diseases | Mendelian randomization | TRIAL | epidemiology | genetics | EPIC-NORFOLK | SERUM-LEVELS | INHIBITOR | HEALTHY-MEN | ARTERY-DISEASE | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | ACUTE CORONARY SYNDROME | ENZYMES | ASSOCIATION | TEKNIKVETENSKAP | Engineering and Technology | Teknik och teknologier | TECHNOLOGY
Journal Article
American Heart Journal, ISSN 0002-8703, 2014, Volume 167, Issue 5, pp. 653 - 659.e4
Background Despite their wide use, whether antiarrhythmic drugs improve survival after out-of-hospital cardiac arrest (OHCA) is not known. The ROC-ALPS is...
Cardiovascular | INTERNATIONAL LIAISON COMMITTEE | CARDIAC & CARDIOVASCULAR SYSTEMS | INTRAVENOUS AMIODARONE | VENTRICULAR-FIBRILLATION | CONSENSUS STATEMENT | AMERICAN-HEART-ASSOCIATION | EMERGENCY CARDIOVASCULAR CARE | CARDIOPULMONARY-RESUSCITATION | STROKE FOUNDATION | SOUTHERN AFRICA | DEFIBRILLATION ENERGY-REQUIREMENTS | Cardiopulmonary Resuscitation - methods | Prospective Studies | Follow-Up Studies | Ventricular Fibrillation - drug therapy | Humans | Out-of-Hospital Cardiac Arrest - etiology | Male | Out-of-Hospital Cardiac Arrest - mortality | Amiodarone - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Heart Rate - drug effects | Out-of-Hospital Cardiac Arrest - therapy | Ventricular Fibrillation - complications | Adult | Female | Drug Therapy, Combination | Double-Blind Method | Ventricular Fibrillation - mortality | Treatment Outcome | Lidocaine - administration & dosage | Anti-Arrhythmia Agents - administration & dosage | Adolescent | North America - epidemiology | Emergency Medical Services | Amiodarone | Lidocaine | Analysis | Methods | Cardiac arrest | Heart | Medical research | Substance abuse treatment | Heart attacks | Hospitals | Research & development--R&D | Ventilation | Licensed products | FDA approval | Cardiopulmonary resuscitation--CPR | Pharmaceuticals
Cardiovascular | INTERNATIONAL LIAISON COMMITTEE | CARDIAC & CARDIOVASCULAR SYSTEMS | INTRAVENOUS AMIODARONE | VENTRICULAR-FIBRILLATION | CONSENSUS STATEMENT | AMERICAN-HEART-ASSOCIATION | EMERGENCY CARDIOVASCULAR CARE | CARDIOPULMONARY-RESUSCITATION | STROKE FOUNDATION | SOUTHERN AFRICA | DEFIBRILLATION ENERGY-REQUIREMENTS | Cardiopulmonary Resuscitation - methods | Prospective Studies | Follow-Up Studies | Ventricular Fibrillation - drug therapy | Humans | Out-of-Hospital Cardiac Arrest - etiology | Male | Out-of-Hospital Cardiac Arrest - mortality | Amiodarone - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Heart Rate - drug effects | Out-of-Hospital Cardiac Arrest - therapy | Ventricular Fibrillation - complications | Adult | Female | Drug Therapy, Combination | Double-Blind Method | Ventricular Fibrillation - mortality | Treatment Outcome | Lidocaine - administration & dosage | Anti-Arrhythmia Agents - administration & dosage | Adolescent | North America - epidemiology | Emergency Medical Services | Amiodarone | Lidocaine | Analysis | Methods | Cardiac arrest | Heart | Medical research | Substance abuse treatment | Heart attacks | Hospitals | Research & development--R&D | Ventilation | Licensed products | FDA approval | Cardiopulmonary resuscitation--CPR | Pharmaceuticals
Journal Article